Weight & metabolic
Mazdutide
IBI362, LY3305677
Mazdutide is a GLP-1 and glucagon receptor dual agonist based on the oxyntomodulin backbone, developed by Innovent and licensed from Eli Lilly. It was approved in China in 2025 for weight management and for type 2 diabetes, and is not approved in the United States.
Also known as: IBI362, LY3305677, OXM analogue
- Status
- Mazdutide is approved in at least one country outside the U.S. but not approved by the FDA.
- Evidence
- Human trials. Published clinical trials in people report results.
- Half-life
- Consistent with once-weekly subcutaneous dosing; a precise value is not established in a US label.
- How it's taken
- Once-weekly subcutaneous injection
- Mechanism
- Incretin (GLP-1 / GIP / glucagon / amylin)
- Pathways
- GLP-1, Glucagon
How Mazdutide works
Mazdutide activates both the GLP-1 receptor and the glucagon receptor. GLP-1 agonism provides the familiar appetite suppression, delayed gastric emptying and glucose-dependent insulin secretion. Glucagon receptor agonism is intended to add energy expenditure and hepatic fat mobilisation — the same rationale as survodutide and pemvidutide — while the GLP-1 component offsets glucagon's hyperglycaemic effect.
What research has looked at
- Phase 3 trials conducted in China reported clinically meaningful weight reduction and HbA1c reduction, supporting its Chinese approvals.
- The dual GLP-1 and glucagon mechanism is associated with reductions in hepatic fat content, an area of active investigation for metabolic dysfunction-associated steatohepatitis.
- It is dosed once weekly.
Evidence level: Human trials. Published clinical trials in people report results. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Gastrointestinal effects typical of the incretin class — nausea, vomiting, diarrhea and decreased appetite — most prominent during dose escalation.
- Increased heart rate is characteristic of this class and may be more pronounced with glucagon co-agonism.
- Glucagon receptor agonism can raise hepatic glucose output; trials monitored glycaemic and hepatic parameters closely.
- It is not approved by the FDA. Material sold in the US as mazdutide is not a regulated pharmaceutical product, and its identity, purity and dose accuracy are unverified.
- The main efficacy and safety data are from a predominantly Chinese trial population; generalisability to other populations is not established.
Sources
- PubMed research on mazdutide GLP-1 glucagon dual agonist · NIH · National Library of Medicine
- DrugBank record for mazdutide · DrugBank
- Active clinical trials for mazdutide · U.S. National Library of Medicine
Track Mazdutide in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Mazdutide FAQ
What is Mazdutide?
Mazdutide is a GLP-1 and glucagon receptor dual agonist based on the oxyntomodulin backbone, developed by Innovent and licensed from Eli Lilly. It was approved in China in 2025 for weight management and for type 2 diabetes, and is not approved in the United States.
How does Mazdutide work?
Mazdutide activates both the GLP-1 receptor and the glucagon receptor. GLP-1 agonism provides the familiar appetite suppression, delayed gastric emptying and glucose-dependent insulin secretion. Glucagon receptor agonism is intended to add energy expenditure and hepatic fat mobilisation — the same rationale as survodutide and pemvidutide — while the GLP-1 component offsets glucagon's hyperglycaemic effect.
Is Mazdutide FDA approved?
No. Mazdutide is approved in at least one country outside the U.S. but not approved by the FDA. Evidence level: human trials. Published clinical trials in people report results.
How is Mazdutide taken?
Once-weekly subcutaneous injection.
What side effects have been reported with Mazdutide?
Reported in the sources: Gastrointestinal effects typical of the incretin class — nausea, vomiting, diarrhea and decreased appetite — most prominent during dose escalation; Increased heart rate is characteristic of this class and may be more pronounced with glucagon co-agonism; Glucagon receptor agonism can raise hepatic glucose output; trials monitored glycaemic and hepatic parameters closely; It is not approved by the FDA. Material sold in the US as mazdutide is not a regulated pharmaceutical product, and its identity, purity and dose accuracy are unverified; The main efficacy and safety data are from a predominantly Chinese trial population; generalisability to other populations is not established.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.